The glucocorticoid insensitivity syndrome.
Lamberts SW.
Horm Res. 1996;45 Suppl 1:2-4. doi: 10.1159/000184815.
Glucocorticoid Resistance.
Nicolaides NC, Charmandari E.
Exp Suppl. 2019;111:85-102. doi: 10.1007/978-3-030-25905-1_6.
Androgen action.
Werner R, Holterhus PM.
Endocr Dev. 2014;27:28-40. doi: 10.1159/000363610. Epub 2014 Sep 9.
Résistances aux hormones stéroïdes : physiologie et pathologie: Pathophysiology of Steroid Resistance Syndrome.
Ramos N, Lombès M.
Ann Endocrinol (Paris). 2016 Oct;77 Suppl 1:S1-S10. doi: 10.1016/S0003-4266(17)30072-0.
Adrenocorticotropin resistance syndromes.
Cooray SN, Chan L, Metherell L, Storr H, Clark AJL.
Endocr Dev. 2008;13:99-116. doi: 10.1159/000134828.
Primary generalized familial and sporadic glucocorticoid resistance (Chrousos syndrome) and hypersensitivity.
Charmandari E, Kino T, Chrousos GP.
Endocr Dev. 2013;24:67-85. doi: 10.1159/000342505. Epub 2013 Feb 1.
Sex-hormone-binding globulin.
Anderson DC.
Clin Endocrinol (Oxf). 1974 Jan;3(1):69-96. doi: 10.1111/j.1365-2265.1974.tb03298.x.
Tissue glucocorticoid resistance/hypersensitivity syndromes.
Kino T, De Martino MU, Charmandari E, Mirani M, Chrousos GP.
J Steroid Biochem Mol Biol. 2003 Jun;85(2-5):457-67. doi: 10.1016/s0960-0760(03)00218-8.
Chrousos syndrome: from molecular pathogenesis to therapeutic management.
Nicolaides NC, Charmandari E.
Eur J Clin Invest. 2015 May;45(5):504-14. doi: 10.1111/eci.12426. Epub 2015 Mar 23.
Androgen action.
Roy AK, Chatterjee B.
Crit Rev Eukaryot Gene Expr. 1995;5(2):157-76. doi: 10.1615/critreveukargeneexpr.v5.i2.30.
